First iVAC 2L case in New Zealand

🚀A new milestone in New Zealand 🚀
We are thrilled to announce the first protected High-Risk PCI with the successful support of iVAC 2L performed by Dr. Sanjeevan Pasupati, the director of structural heart disease & cardiovascular research unit and Dr. Madhav Menon at Waikato hospital in Hamilton.

“This technology gives us better blood pressure support for very sick hearts while performing complex interventions,” Dr Menon said.
“It allows us to perform these procedures more safely with better clinical outcomes for the patient and less stress for our team.”

👨‍⚕️ Procedure: 3-vessel disease, male, 75 years old, EF 20%, mild MR, COPD. Severe Left main, severe Mid LAD and mid CX stenosis.
In total 2 stents deployed. Overall PCI support with iVAC 2L was 100 minutes. Estimated support of iVAC 2L was 1.4-1.6 L/min and ACT target around 300. Patient was hemodynamic stable during procedure.  Femoral artery closed with double Perclose ProGlide closure device. Patient is ok and discharged.

🌟Congratulations and a huge thanks to Dr. Sanjeevan Pasupati, Dr. Madhav Menon, cathlab team and our local partner Intervene Medical.


Case-in-a-box congress - video 7

Case-in-a-box congress - video 6

Case-in-a-box congress - video 5

Case-in-a-box congress - video 4

Case-in-a-box congress - video 3

Case-in-a-box congress - video 2

Case-in-a-box congress - video 1

Case-in-a-box number 2: Al Qassimi Hospital February 2023

Case-in-a-box number 1: Al Qassimi Hospital February 2023

iVAC 2L Procedure Steps

iVAC 2L Setup

iVAC 2L Trouble Shooting

iVAC 2L Clinical Effect

Complete webinar

First iVAC 2L case in New Zealand